QIAGEN N.V. — FY2015 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2015. This is an audited annual report, not a standalone fourth-quarter filing; the supplied text does not provide clear fourth-quarter financial results. Financial statements are prepared under U.S. GAAP.
Business context
QIAGEN provides molecular testing and “Sample to Insight” products—including consumables, instruments and bioinformatics—to Molecular Diagnostics, Applied Testing, Pharma and Academia customers. Consumables and related revenues represented about 87% of 2015 sales; instrumentation represented about 13%. The company reported one operating segment and operated in more than 130 countries.
Key financial metrics
| Metric | FY2015 | FY2014 |
|---|---|---|
| Net sales | $1,281.0 million | $1,344.8 million |
| Gross profit / margin | $826.4 million / 65% | $864.9 million / 64% |
| Operating income / margin | $175.7 million / 13.7% | $160.8 million / 12.0% |
| Net income attributable to QIAGEN N.V. | $127.1 million | $116.6 million |
| Diluted earnings per share | $0.54 | $0.48 |
| Cash from operating activities | $317.5 million | $288.0 million |
| Cash and cash equivalents | $290.0 million | $392.7 million |
| Short-term investments | $130.8 million | $184.0 million |
| Working capital | $693.3 million | $717.1 million |
| Long-term debt, net of current portion | $1,059.6 million | $1,041.0 million |
| Total equity | $2,562.0 million | $2,658.0 million |
Gross margin and operating margin are calculated from reported amounts and are approximate. No amount of long-term debt was current at year-end 2015. The company also had an unused €400 million revolving credit facility, extended to December 2020, and €36.6 million of other unused credit lines.
Material changes versus FY2014
- Reported sales fell 5%, largely due to currency: management estimated an approximately eight-percentage-point adverse currency impact. On a currency-adjusted basis, sales increased; excluding currency effects and the expected U.S. HPV decline, management reported approximately 6% growth.
- Currency-adjusted contributions from consumables and related revenue grew 3%, and instruments grew 5%. Acquisitions contributed approximately two percentage points of total sales growth before currency effects.
- Molecular Diagnostics sales declined 7% as reported, including an ongoing 43% decline in U.S. HPV test sales, equal to about 3% of total sales. Core Molecular Diagnostics growth was approximately 7% before currency effects and the HPV decline.
- Operating income increased about 9%, and net income attributable to QIAGEN increased about 9%, despite lower reported sales. Operating expenses declined, including lower R&D and general and administrative, restructuring and integration costs.
- Operating cash flow increased to $317.5 million. Cash declined by $102.7 million, primarily reflecting financing outflows of $258.6 million and investing outflows of $146.2 million, partly offset by operating cash generation.
Outlook, commentary and risks
- No specific quantitative FY2016 revenue or earnings guidance is stated in the supplied filing text. Management said operations, existing cash and available financing were expected to fund planned operations and expansion during the coming year, while noting that a downturn or weaker sales could affect liquidity.
- Strategic priorities include expanding QuantiFERON-TB, QIAsymphony, personalized healthcare, bioinformatics and next-generation sequencing. GeneReader NGS was introduced in late 2015; adoption, assay availability and regulatory approvals will influence future sales. QIAsymphony placements exceeded 1,500 cumulatively.
- Management expected continued R&D investment and additional integration costs in 2016. New product development, market acceptance, regulatory clearance and reimbursement remain important uncertainties.
- Major disclosed risks include foreign-exchange movements, pricing and reimbursement pressure, reduced research funding, competition, acquisition integration, dependence on product innovation, regulatory changes, supply interruptions, cybersecurity and intellectual-property risks.
- Debt-related matters include $730 million principal of cash convertible notes issued in 2014, maturing in 2019 and 2021, and warrants covering up to 25.8 million shares. The company warned that note accounting creates interest expense above coupon rates and that warrants could dilute shareholders if applicable share-price conditions are met.
- Unusual items included a $7.6 million loss on repayment of the QIAGEN Finance loan and repurchase of its warrant agreement, $6.0 million of realized losses on short-term investments, and $2.2 million of impairments to cost-method investments. The effective tax rate was 4.3%, reflecting geographic tax differences and tax benefits; the filing cautions that tax-law changes or challenges could raise the rate.
- Potential acquisition-related contingent payments total up to $67.8 million, of which $17.7 million was recorded as fair value at year-end. The company also disclosed $18.1 million of estimated uncertain-tax-position liabilities, excluding them from its contractual-obligations table because payment timing could not be reasonably estimated.
- Management stated that pending litigation was not expected, based on information then available, to have a material adverse effect; outcomes remain uncertain. The filing reported unqualified audit opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether currency-adjusted growth, particularly in core Molecular Diagnostics, continues to offset reported foreign-exchange pressure and U.S. HPV declines.
- Whether GeneReader, QIAsymphony and related consumables gain adoption at a pace that supports the required investment and anticipated recurring sales.
- Debt maturities, the cash-settlement terms of convertible notes, potential warrant dilution, and the company’s capacity to meet contingent acquisition payments.
- The sustainability of the low effective tax rate and the outcomes of disclosed U.S. and German tax examinations.
- The sensitivity of reported goodwill and intangible assets—approximately $1.88 billion and $636 million, respectively—to future performance and impairment assumptions.